Skip to main content
TLSI
NASDAQ Industrial Applications And Services

TriSalus 10-Q: Q3 Revenue $12.9M, Net Loss Narrows to $8.9M, $41.1M Cash

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$3.001
Mkt Cap
$198.27M
52W Low
$2.2
52W High
$7.95
52W Position info
36% above low
Off High info
62% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

TLSI sits 36% above its 52-week low of $2.2.

Summary

TriSalus' Q3 10-Q shows revenue up 11.3% to $12.9 million with 86.2% gross margin, an $8.9 million net loss, and $41.1 million of cash — but a still-unremediated material weakness and a sixth OrbiMed covenant amendment.


Key Events · Earnings and Guidance · TLSI

  • Q3 Revenue $12.9M, Up 11.3%

    Revenue rose to $12.9 million from $11.6 million a year earlier, with gross margin improving to 86.2% from 83.5% on lower cost per TriNav unit.

  • Net Loss Narrows to $8.9M

    Q3 net loss was $8.9 million versus $10.8 million a year earlier; the nine-month loss fell to $16.5 million from $29.5 million, helped by $5.8 million and $7.1 million of non-cash fair-value gains on warrant and earnout liabilities.

  • Sales Spend Up 56.9%, R&D Down 44.1%

    Sales and marketing expense rose to $10.7 million from $6.8 million while R&D fell to $3.2 million from $5.7 million as nelitolimod trial costs did not recur.

  • Cash $41.1M After $42.6M Raise

    Cash and equivalents stood at $41.1 million at September 30, 2026 versus $20.4 million at December 31, 2025, following $42.6 million of net proceeds from the February 2026 equity offering.


Analysis · TLSI · Industrial Applications And Services

The 10-Q fills in the numbers behind this morning's 8-K. Revenue grew 11.3% to $12.9 million and gross margin improved to 86.2%, but that growth is being bought: sales and marketing expense jumped 56.9% to $10.7 million in the quarter, which is why full-year guidance was trimmed to $46-48 million. The balance sheet is the reassuring part — $41.1 million of cash after February's $42.6 million equity raise, against $32.4 million of OrbiMed term debt that does not begin amortizing while TriNav revenue clears the amended thresholds. Two items carry real weight: the material weakness in internal controls over significant-transaction accounting is still unremediated, and the company keeps leaning on OrbiMed amendments (the sixth, signed September 29, 2026, lowered three revenue thresholds for a $1.09 million fee) to stay ahead of the repayment trigger. Net loss of $8.9 million for the quarter was flattered by $0.7 million of non-cash gains on warrant and earnout remeasurement — mark-to-market entries driven by the share price, not cash or new dilution.

How filings like this one have moved

In the 30 days to Nov 10, 2026, 36.4% of the 3168 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, TLSI was trading at $3.00 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $198.3M. The 52-week trading range was $2.20 to $7.95. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

TLSI - Latest Insights

TLSI
Nov 10, 2026, 8:06 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.00
Real-time Price: $3.00 info
Change: -$0.0005 (-0.02%) info
Market Cap: $198.27M info
TLSI
Nov 10, 2026, 8:05 AM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $3.22
Real-time Price: $3.00 info
Change: -$0.220 (-7%) info
Market Cap: $198.27M info
TLSI
Sep 22, 2026, 4:15 PM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $4.93
Real-time Price: $3.00 info
Change: -$1.93 (-39%) info
Market Cap: $198.27M info
TLSI
May 18, 2026, 4:42 PM EDT
Filing Type: 4
Importance Score:
8
Price at Filing: $2.97
Real-time Price: $3.00 info
Change: +$0.030 (+1%) info
Market Cap: $198.27M info
TLSI
May 12, 2026, 4:08 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $4.50
Real-time Price: $3.00 info
Change: -$1.50 (-33%) info
Market Cap: $198.27M info